Search

Your search keyword '"Liu, Yonghong"' showing total 3,325 results
Start Over Author "Liu, Yonghong"
3,325 results on '"Liu, Yonghong"'

54. Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson’s disease in Chinese population

Author

Pan, Hongxu, Liu, Zhenhua, Ma, Jinghong, Li, Yuanyuan, Zhao, Yuwen, Zhou, Xiaoxia, Xiang, Yaqin, Wang, Yige, Zhou, Xun, He, Runcheng, Xie, Yali, Zhou, Qiao, Yuan, Kai, Xu, Qian, Sun, Qiying, Wang, Junling, Yan, Xinxiang, Zhang, Hainan, Wang, Chunyu, Lei, Lifang, Liu, Weiguo, Wang, Xuejing, Ding, Xuebing, Wang, Tao, Xue, Zheng, Zhang, Zhentao, Chen, Ling, Wang, Qing, Liu, Yonghong, Tang, Jiayu, Zhang, Xuewei, Peng, Shifang, Wang, Chaodong, Ding, Jianqing, Liu, Chunfeng, Wang, Lijuan, Chen, Haibo, Shen, Lu, Jiang, Hong, Wu, Xinyin, Tan, Hongzhuan, Luo, Dan, Xiao, Shuiyuan, Chen, Xiang, Tan, Jieqiong, Hu, Zhengmao, Chen, Chao, Xia, Kun, Zhang, Zhuohua, Foo, Jia Nee, Blauwendraat, Cornelis, Nalls, Mike A., Singleton, Andrew B., Liu, Jun, Chan, Piu, Zheng, Houfeng, Li, Jinchen, Guo, Jifeng, Yang, Jian, and Tang, Beisha

Published
2023
Full Text
View/download PDF

58. Chemotherapy-induced oral mucositis induced by low dose methotrexate: a case report and literature review

Author

WANG Shanshan, MA Xixing, LI Yanling, and LIU Yonghong

Subjects
methotrexate, chemotherapy-induced oral mucositis, psoriasis vulgaris, myelosuppression, chronic periodontitis, granulocyte colony stimulating factor, risk factors, Medicine
Abstract

Objective To investigate the diagnosis and treatment for oral mucositis induced by low-dose methotrexate and to provide a reference for clinicians. Methods A case of severe chemotherapy-induced oral mucositis caused by short-term use of low-dose methotrexate (the maximum cumulative dose within 1 week) was reported and reviewed in combination with the literature. Results The patient was treated with low-dose methotrexate (2.5 mg orally every other day at weeks 1, 2, and 4; the third week, 2.5 mg each time for 3 consecutive days for twice, with a maximum cumulativedose of 15 mg within a week). After irregular medication for approximately three weeks, the patient gradually developed severe erosion of the lips, pain, difficulty eating, and skin erosion on both legs. Methotrexate was stopped after admission, and local symptomatic treatments such as Kangfuxin solution were given. Recombinant human granulocyte colony-stimulating factor was used systemically when combined with neutropenia. After treatment, the chemotherapy-induced oral mucositis and skin lesions were improved. A literature review shows that chemotherapy-induced oral mucositis is a toxic reaction to high-dose methotrexate, while cases of severe chemotherapy-induced oral mucositis caused by low-dose methotrexate are rare. Studies have found that the more risk factors patients have, such as poor local oral conditions and systemic diseases such as liver and kidney dysfunction and diabetes, the higher the risk of chemotherapy-induced oral mucositis. Clinicians should cooperate with dentists to address oral diseases as much as possible before using chemotherapy drugs. In addition, when ordering patients to take methotrexate, we should pay attention to the patient's general condition and susceptibility factors, standardize the frequency and dose of administration, adopt personalized treatment plans, and give patients detailed medication education to prevent the occurrence of adverse consequences caused by medication errors. If methotrexate poisoning occurs, the drug should be stopped in time, detoxification and active symptomatic and supportive treatment should be given. Basic oral care, cryotherapy, laser therapy, nutritional support and analgesic drugs are common treatments for chemotherapy-induced oral mucositis. Systemic administration of granulocyte colony-stimulating factor may be considered when accompanied by neutropenia. Conclusion It is necessary to be alert to the occurrence of severe chemotherapy-induced oral mucositis caused by low-dose methotrexate in clinical practice.

Published
2023
Full Text
View/download PDF

68. 2{\pi} scaling law during inviscid fluid pinch-off and satellite droplets formation

Author

Li, Dege, Cao, Yi, Huang, Bingfang, Liu, Yonghong, and Zhang, Yanzhen

Subjects
Physics - Fluid Dynamics
Abstract

Pinch-off and satellite droplets formation during breakup of near-inviscid liquid bridge sandwiched between two given equal and coaxial circular plates have been investigated. The breakup always results in the formation of a spindle shape which is the precursor of the satellite droplet at the moment of pinch-off. Interestingly, the slenderness of this spindle is always bigger than 2{\pi} and always results in the formation of only one satellite droplet regardless of the surface tension and the slenderness of the liquid bridge. We predict the cone angle of this spindle formed during the pinch-off of inviscid fluids should be 18.086122158...{\deg}. After pinch-off, the satellite droplets will drift out of the pinch-off regions in the case of symmetrical short bridge, and merge again with the sessile drop in the case of unsymmetrical long bridge. We demonstrate that the velocity of the satellite droplet is consistent with a scaling model based on a balance between capillary forces and the inertia at the pinch-off region., Comment: 6 pages, 5 figures

Published
2021

93. Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin

Author

Zheng, Jianwei, Wang, Junfeng, Wang, Qian, Zou, Hongye, Wang, Hong, Zhang, Zhenhua, Chen, Jianghe, Wang, Qianqian, Wang, Panxia, Zhao, Yueshan, Lu, Jing, Zhang, Xiaolei, Xiang, Songtao, Wang, Haibin, Lei, Jinping, Chen, Hong-Wu, Liu, Peiqing, Liu, Yonghong, Han, Fanghai, and Wang, Junjian

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Genetics, Biotechnology, Aging, Urologic Diseases, Cancer, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Aetiology, ROR gamma, Castration-resistant prostate cancer, Nuclear receptor, Antagonist, Elaiophylin, RORγ, Pharmacology and pharmaceutical sciences
Abstract

Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor RORγ as a novel therapeutic target for CRPC. Here, we reveal that elaiophylin (Elai), an antibiotic from Actinomycete streptomyces, is a novel RORγ antagonist and showed potent antitumor activity against CRPC in vitro and in vivo. We demonstrated that Elai selectively binded to RORγ protein and potently blocked RORγ transcriptional regulation activities. Structure-activity relationship studies showed that Elai occupied the binding pocket with several key interactions. Furthermore, Elai markedly reduced the recruitment of RORγ to its genomic DNA response element (RORE), suppressed the expression of RORγ target genes AR and AR variants, and significantly inhibited PCa cell growth. Importantly, Elai strongly suppressed tumor growth in both cell line based and patient-derived PCa xenograft models. Taken together, these results suggest that Elai is novel therapeutic RORγ inhibitor that can be used as a drug candidate for the treatment of human CRPC.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results